Novo Nordisk has announced that it will be investing €432 million ($510 million) in its tableting facility in Athlone, Ireland, to increase its capacity to manufacture oral GLP-1 treatments.
In addition to producing more GLP-1s, the company is using the investment to upgrade and retrofit its facility. It intends to turn Ireland into a hub for providing high-quality oral medications to markets outside the U.S.
The project will create up to 500 jobs in construction, building on a site that covers 45 acres. Some of the construction projects have already begun and all are expected to be complete between 2027 and 2028.